Thierry Fest

Thierry Fest


Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MKMarta Kulis
Marta Kulis
AMAngelika Merkel
Angelika Merkel
SHSimon Heath
Simon Heath
AQAna C Queirós
Ana C Queirós
RSRonald P Schuyler
Ronald P Schuyler
JMJosé I Martín-Subero
José I Martín-Subero

9 June 2015 in Molecular Oncology
Verified
Journal Article
Open access
MMMartine Mazel
Martine Mazel
WJWilliam Jacot
William Jacot
KPKlaus Pantel
Klaus Pantel
KBKai Bartkowiak
Kai Bartkowiak
DTDelphine Topart
Delphine Topart
Catherine Alix-PanabieresCatherine Alix-Panabieres
Catherine Alix-Panabieres
Immune checkpoint regulators such as PD‐L1 have become exciting new therapeutic targets leading to long lasting remissions in patients with advanced malignancies. However, in view of the remarkable costs and the toxicity profiles of these therapies, predictive biomarkers able to discriminate responders from non‐responders are urgently needed. In the present paper, we provide evidence that PD‐L1 is frequently expressed on metastatic cells circulating in the blood of hormone receptor‐positive, HER2‐negative breast cancer patients. We performed western blot, flow cytometry and immunocytochemical analyses to demonstrate the specificity of the PDL1 antibody used in our study and established immunoscores for PDL1 expression on single tumor cells. We then selected sixteen patients with circulating tumor cells (CTCs) using the CellSearch® system and found PD‐L1(+) CTCs in 11 patients (68.8%). The fraction of PD‐L1(+) CTCs varied from 0.2 to 100% in individual patients. This is the first report demonstrating the expression of PD‐L1 on CTCs. The established CTC/PD‐L1 assay can be used for liquid biopsy in future clinical trials for stratification and monitoring of cancer patients undergoing immune checkpoint blockade.

12 June 2014 in Blood
Verified
Journal Article
Open access
PDF file
KBKheira Beldjord
Kheira Beldjord
SCSylvie Chevret
Sylvie Chevret
VAVahid Asnafi
Vahid Asnafi
FHFrançoise Huguet
Françoise Huguet
MBMarie-Laure Boulland
Marie-Laure Boulland
HDHervé Dombret
Hervé Dombret
With intensified pediatric-like therapy and genetic disease dissection, the field of adult acute lymphoblastic leukemia (ALL) has evolved recently. In this new context, we aimed to reassess the value of conventional risk factors with regard to new genetic alterations and early response to therapy, as assessed by immunoglobulin/T-cell receptor minimal residual disease (MRD) levels. The study was performed in 423 younger adults with Philadelphia chromosome–negative ALL in first remission (265 B-cell precursor [BCP] and 158 T-cell ALL), with cumulative incidence of relapse (CIR) as the primary end point. In addition to conventional risk factors, the most frequent currently available genetic alterations were included in the analysis. A higher specific hazard of relapse was independently associated with postinduction MRD level ≥10−4 and unfavorable genetic characteristics (ie, MLL gene rearrangement or focal IKZF1 gene deletion in BCP-ALL and no NOTCH1/FBXW7 mutation and/or N/K-RAS mutation and/or PTEN gene alteration in T-cell ALL). These 2 factors allowed definition of a new risk classification that is strongly associated with higher CIR and shorter relapse-free and overall survival. These results indicate that genetic abnormalities are important predictors of outcome in adult ALL not fully recapitulated by early response to therapy. Patients included in this study were treated in the multicenter GRAALL-2003 and GRAALL-2005 trials. Both trials were registered at http://www.clinicaltrials.gov as #NCT00222027 and #NCT00327678, respectively.

15 April 2014 in Leukemia
Verified
Journal Article
Open access
PDF file
DRD Rossille
D Rossille
MGM Gressier
M Gressier
DDD Damotte
D Damotte
DMD Maucort-Boulch
D Maucort-Boulch
CPCeline PANGAULT
Celine PANGAULT
PGP Godemer
P Godemer
The dosage of soluble programmed cell death ligand 1 (sPD-L1) protein in the blood of adults with cancer has never been performed in a prospective patient cohort. We evaluated the clinical impact of sPD-L1 level measured at the time of diagnosis for newly diagnosed diffuse large B-cell lymphoma (DLBCL). Soluble PD-L1 was measured in the plasma of 288 patients enrolled in a multicenter, randomized phase III trial that compared R-high-dose chemotherapy with R-CHOP. The median follow-up was 41.4 months. A cutoff of 1.52 ng/ml of PD-L1 level was determined and related to overall survival (OS). Patients with elevated sPD-L1 experienced a poorer prognosis with a 3-year OS of 76% versus 89% (P<0.001). Considering clinical characteristics, the multivariate analysis retained this biomarker besides bone marrow involvement and abnormal lymphocyte–monocyte score as independently related to poor outcome. sPD-L1 was detectable in the plasma and not in the serum, found elevated in patients at diagnosis compared with healthy subjects and its level dropped back to normal value after CR. The intention-to-treat analysis showed that elevated sPD-L1 was associated with a poorer prognosis for patients randomized within the R-CHOP arm (P<0.001). Plasma PD-L1 protein is a potent predicting biomarker in DLBCL and may indicate usefulness of alternative therapeutic strategies using PD-1 axis inhibitors.

1 August 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
FUFabrice Uhel
Fabrice Uhel
IAImane Azzaoui
Imane Azzaoui
MGMurielle Grégoire
Murielle Grégoire
CPCeline PANGAULT
Celine PANGAULT
JDJoelle Dulong
Joelle Dulong
KTKarin TARTE
Karin TARTE
Rationale: Sepsis induces a sustained immune dysfunction responsible for poor outcome and nosocomial infections. Myeloid-derived suppressor cells (MDSCs) described in cancer and inflammatory processes may be involved in sepsis-induced immune suppression but their clinical impact remains poorly defined. Objectives: To clarify phenotype, suppressive activity, origin, and clinical impact of MDSCs in septic patients. Methods: Peripheral blood transcriptomic analysis was performed on 29 septic patients and 15 healthy donors. A second cohort of 94 consecutive septic patients, 11 severity-matched intensive care patients and 67 healthy donors was prospectively enrolled for flow cytometry and functional experiments. Measurements and Main Results: Genes involved in MDSC suppressive functions, including S100A12, S100A9, MMP8 and ARG1, were upregulated in the peripheral blood of septic patients. CD14posHLA-DRlow/neg monocytic (M)-MDSCs were expanded in intensive care septic and non-septic patients and CD14negCD15pos low-density granulocytes/ granulocytic (G)-MDSCs were more specifically expanded in septic patients (p<.001). Plasma levels of MDSC mediators S100A8/A9, S100A12, and Arginase 1 were significantly increased. In vitro, CD14pos- and CD15pos-cell depletion increased T-cell proliferation in septic patients. G-MDSCs, made of immature and mature granulocytes expressing high levels of degranulation markers, were specifically responsible for arginase 1 activity. High initial levels of G-MDSCs, arginase 1, and S100A12 but not M-MDSCs were associated with subsequent occurrence of nosocomial infections. Conclusions: M-MDSCs and G-MDSCs strongly contribute to T-cell dysfunction in septic patients. More specifically, G-MDSCs producing arginase 1 are associated with a higher incidence of nosocomial infections and appear to be major actors of sepsis-induced immune suppression.

19 September 2006 in Blood
Verified
Journal Article
Open access
PDF file
PAPatricia Amé
Patricia Amé
HHHélène Maby-El Hajjami
Hélène Maby-El Hajjami
CMCéline Monvoisin
Céline Monvoisin
RJRachel Jean
Rachel Jean
DMDelphine Monnier
Delphine Monnier
KTKarin TARTE
Karin TARTE
Accumulating evidence indicates that the cellular microenvironment plays a key role in follicular lymphoma (FL) pathogenesis, both within tumor lymph nodes (LNs) and in infiltrated bone marrow where ectopic LN-like reticular cells are integrated within malignant B-cell nodular aggregates. In normal secondary lymphoid organs, specific stromal cell subsets provide a highly specialized microenvironment that supports immune response. In particular, fibroblastic reticular cells (FRCs) mediate immune cell migration, adhesion, and reciprocal interactions. The role of FRCs and their postulated progenitors, that is, bone marrow mesenchymal stem cells (MSCs), in FL remains unexplored. In this study, we investigated the relationships between FRCs and MSCs and their capacity to sustain malignant B-cell growth. Our findings strongly suggest that secondary lymphoid organs contain MSCs able to give rise to adipocytes, chondrocytes, osteoblasts, as well as fully functional B-cell supportive FRCs. In vitro, bone marrow–derived MSCs acquire a complete FRC phenotype in response to a combination of tumor necrosis factor-α and lymphotoxin-α1β2. Moreover, MSCs recruit primary FL cells that, in turn, trigger their differentiation into FRCs, making them able to support malignant B-cell survival. Altogether, these new insights into the cross talk between lymphoma cells and their microenvironment could offer original therapeutic strategies.